Moreadith Randall 4
4 · Serina Therapeutics, Inc. · Filed Jan 14, 2026
Insider Transaction Report
Form 4
Moreadith Randall
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2026-01-13$0.06/sh+5,416$325→ 5,416 total - Sale
Common Stock
2026-01-13$2.50/sh−5,416$13,540→ 0 total - Exercise/Conversion
Common Stock
2026-01-14$0.06/sh+1,084$65→ 1,084 total - Sale
Common Stock
[F1]2026-01-14$2.50/sh−1,084$2,713→ 0 total - Exercise/Conversion
Stock Option (right to buy)
[F2]2026-01-13−5,416→ 333,770 totalExercise: $0.06Exp: 2031-05-06→ Common Stock (5,416 underlying) - Exercise/Conversion
Stock Option (right to buy)
[F2]2026-01-14−1,084→ 332,686 totalExercise: $0.06Exp: 2031-05-06→ Common Stock (1,084 underlying)
Footnotes (2)
- [F1]The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.54 to $2.50. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- [F2]The stock options are fully vested.
Signature
/s/ Randall Moreadith|2026-01-14